The Hellenic Chest Diseases Society (H.C.D.S), supporting research in pulmonology, is proceeding to the initial funding of the company RespiFit LTD for the development of a prototype device for the detection of tuberculosis mycobacterium dispersed in air. About one quarter of the world population is thought to have latent infection with TB and more than one million people die each year.
RespiFit is a Digital Health SME providing personalized respiratory disease management and focusing on the intelligent monitoring of chronic respiratory diseases (e.g., asthma, COPD) as well as bio-safety against infectious disease agents.
We wish to RespiFit Good luck and the best results!